Study of 3 Doses of ARD-0403 in Testosterone Deficient Men
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men
Lead SponsorArdana Bioscience Ltd
StatusCompleted No Results Posted
The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.
Inclusion Criteria: Testosterone deficiency Normal BMI Exclusion Criteria: Previous treatment with testosterone replacement therapy within 4 weeks Moderate-severe benign prostatic hypertrophy, or prostatic cancer Haematocrit >50%